The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

1002753107. Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. Journal of ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Breast cancer subtypes are primarily categorized by the presence or absence of three key receptors: estrogen receptor (ER), progesterone receptor (PR), and the epidermal growth factor receptor 2 ...

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor receptor inhibitor ... regulatory pathway, according to the company website.

Anxiety disorders, characterized by an excessive apprehension about real or perceived threats and dysfunctional behaviors ...

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...